The FDA has given the green light to a new weight-loss drug from Eli Lilly & Co., named Zepbound. This injectable drug, containing tirzepatide, the same ingredient as Eli Lilly’s diabetes drug Mounjaro, is designed for people struggling with obesity or being overweight, particularly those with weight-related conditions like high blood pressure.
The drug, recommended alongside a lower-calorie diet and regular physical activity, has shown promise in clinical trials, boasting a weight reduction of up to 22%.
Eli Lilly officials are optimistic about Zepbound’s impact, emphasizing its potential benefits for both diabetes and non-diabetes populations. However, concerns have been raised about the side effects, including gastrointestinal issues, and caution is advised for individuals with specific medical histories.
As the demand for weight-loss medications rises, fueled by the obesity epidemic in the United States, this new drug joins the ranks of effective treatments, including semaglutide used in Ozempic and Wegovy. The surge in demand, however, has led to challenges in ensuring an adequate supply and proper management by healthcare professionals.
While the obesity medicine field celebrates these advancements, critics highlight potential risks, emphasizing the need for careful monitoring and prescription management to avoid unintended consequences, especially for those without diabetes.
As Zepbound enters the market with a list price of $1,059, the medical community remains cautiously optimistic, recognizing the importance of these medications in addressing the chronic condition of obesity and its associated health risks.
SUPPORT NIGERIAN CANADIAN NEWSPAPER CANADA
If you like our work and want to keep enjoying what we offer, kindly support us by donating to the Nigerian Canadian News by clicking here
Share your thoughts in the comments section below
Do you want to share any news or information with us? If yes, contact the publisher at publisher@test1.nascitest.club
